ODI Phaa AB announced that the Coany has entered through its PoPolish subsidiary into a collaboration agreement with Synoptis Pharma Sp. Z o.o. under which ODI becomes the exclusive supply partner for medicinal cannabis flos products to Synoptis for a period of 5 plus additional optional 3.5 years covering all Eastern and South Eastern European markets, including Poland, Czech Republic, Ukraine, Croatia etc. ODI has secured a prime pharmaceutical company in the Eastern European markets as its collaboration partner.

With this agreement ODI teams up with one of the biggest pharmaceutical companies in the Eastern European markets in order to provide the efficient supply of medicinal cannabis to patients. Under the Agreement, Synoptis will exclusively source medicinal cannabis from ODI to facilitate the distribution of medicinal cannabis under the existing pharmaceutical and medicinal brands of Synoptis. The Agreement covers 23 countries and covers a range of medicinal cannabis products.

With the Agreement in place ODI establishes itself as a main supply partner of medicinal cannabis in all Eastern European markets. Immediate start of sales: Also, the Agreement implicates that ODI will generate first sales from Project Poland latest in Fourth Quarter/2023. The products will be marketed and distributed by Synoptis.

Market: With the Agreement with Synoptis, ODI significantly expands its market reach from Poland only to now all countries in Eastern Europe that already legalized medicinal cannabis or will do so in the coming years. Also, ODI will work together with Synoptis to promote the legal status of the products and sales in these countries.